Abstract Background A previous European Headache Federation (EHF) guideline
addressed the use of monoclonal antibodies targeting the calcitonin gene-related peptide …

It has been more than three decades since the first monoclonal antibody was approved by
the United States Food and Drug Administration (US FDA) in 1986, and during this time …

Objective To incorporate recent research findings, expert consensus, and patient
perspectives into updated guidance on the use of new acute and preventive treatments for …

Abstract Treatment of migraine is on the cusp of a new era with the development of drugs
that target the trigeminal sensory neuropeptide calcitonin gene-related peptide (CGRP) or its …

Background We tested erenumab, a fully human monoclonal antibody that inhibits the
calcitonin gene–related peptide receptor, for the prevention of episodic migraine. Methods …

Background A substantial proportion of patients with migraine does not respond to, or
cannot tolerate, oral preventive treatments. Erenumab is a novel CGRP-receptor antibody …

Objective To evaluate the efficacy and safety of galcanezumab, a humanized monoclonal
antibody that selectively binds to calcitonin gene-related peptide, in the preventive treatment …

Objective The goal of this narrative review is to provide an overview of migraine
pathophysiology, with an emphasis on the role of calcitonin gene‐related peptide (CGRP) …

Background In this study, we aimed to evaluate the efficacy, safety, and tolerability of
atogepant for the preventive treatment of chronic migraine. Methods We did this randomised …

Migraine is one of the most prevalent and disabling diseases worldwide, but until recently,
few migraine-specific therapies had been developed. Extensive basic and clinical scientific …